EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Use of Real‐World Claims Data to Assess the Prevalence of Concomitant Medications to Inform Drug–Drug Interaction Risk in Target Patient Populations

Alice S Tang iD, Logan Brooks iD, Denise M Boudreau, Pascal Chanu iD, Amita Joshi iD, Bianca Vora iD, Rui Zhu iD

Clinical Pharmacology & Therapeutics · 2025-07 · 118 (1) · 146-155

DOI: 10.1002/cpt.3652 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Pharmacology & Therapeutics, 2025-04. Verfasst von Alice S Tang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Pharmacology, Genentech, Inc., South San Francisco, California, USA. Hauptthemen laut MEDLINE: Breast Neoplasms, Drugs, Investigational. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Genentech Inc.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

A common issue in clinical drug development involves drug–drug interactions (DDI) that may lead to altered drug exposure and subsequent altered safety and efficacy of an investigational drug or concomitant medications (conmeds) in the target patient population. The drug development pipeline therefore involves DDI risk assessment of the investigational drug based on in vitro studies, in silico modeling, and clinical trials. Real‐world data (RWD), particularly claims databases with reliable information on pharmacy dispensing, provide an opportunity to understand conmeds usage in the target indication in a real‐world setting as one approach to assess potential DDI risk. We describe two cases of characterizing DDI‐related conmeds usage with a large closed US‐based claims database, IQVIA PharMetrics® Plus, and identified potential DDI risk for multiple sclerosis and hormone receptor‐positive breast cancer. For example, prevalent and chronic use of statins (atorvastatin and simvastatin), which are CYP3A4 substrates, were identified among both disease cases. Further examples, limitations, and future directions are also discussed. These insights can therefore help augment decision‐making during clinical drug research and development.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsDrugs, InvestigationalHumansDrug InteractionsFemaleRisk AssessmentDatabases, FactualMultiple SclerosisMiddle AgedHydroxymethylglutaryl-CoA Reductase InhibitorsUnited StatesMalePrevalenceAdultSimvastatinAgedAtorvastatinInsurance Claim Review

Substanzen

Hydroxymethylglutaryl-CoA Reductase InhibitorsDrugs, InvestigationalSimvastatinAtorvastatin

Autor:innen und Institutionen

  • Clinical Pharmacology, Genentech, Inc., South San Francisco, California, USA.
  • Product Development Data Science and Real World Data Science, Genentech, Inc., South San Francisco, California, USA.
  • Clinical Pharmacology, Genentech/Roche, Inc., Lyon, France.

ORCID-Profile: Alice S Tang, Logan Brooks, Pascal Chanu, Amita Joshi, Bianca Vora, Rui Zhu

Förderung

  • Genentech Inc

Zitieren

APA

Tang, A. S., Brooks, L., Boudreau, D. M., Chanu, P., Joshi, A., Vora, B., & Zhu, R. (2025). Use of Real‐World Claims Data to Assess the Prevalence of Concomitant Medications to Inform Drug–Drug Interaction Risk in Target Patient Populations. Clinical Pharmacology & Therapeutics, 118(1), 146-155. https://doi.org/10.1002/cpt.3652

Vancouver

Tang AS, Brooks L, Boudreau DM, Chanu P, Joshi A, Vora B, et al. Use of Real‐World Claims Data to Assess the Prevalence of Concomitant Medications to Inform Drug–Drug Interaction Risk in Target Patient Populations. Clinical Pharmacology & Therapeutics. 2025;118(1):146-155. doi:10.1002/cpt.3652

BibTeX
@article{Tang2025,
  author = {Tang, Alice S and Brooks, Logan and Boudreau, Denise M and Chanu, Pascal and Joshi, Amita and Vora, Bianca and Zhu, Rui},
  title = {Use of Real‐World Claims Data to Assess the Prevalence of Concomitant Medications to Inform Drug–Drug Interaction Risk in Target Patient Populations},
  journal = {Clinical Pharmacology & Therapeutics},
  year = {2025},
  volume = {118},
  number = {1},
  pages = {146--155},
  doi = {10.1002/cpt.3652}
}
Kostenlos starten →